Philip Tsai insider trades: Immunome (IMNM) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Philip reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | IMNM | ↑ Buy | 10,000 | $20.49 | $205K | Direct | Dec 22, 2025 (3d) |
| Mar 24, 2025 | IMNM | ↑ Buy | 12,300 | $8.42 | $104K | Direct | Mar 25, 2025 (1d) |
| Nov 21, 2024 | IMNM | ↑ Buy | 21,000 | $9.43 | $198K | Direct | Nov 25, 2024 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMNM insiders
Open-market trades in the last 12 months
About Philip Tsai's insider trades
Philip Tsai is Chief Technical Officer at Immunome (IMNM). Since Nov 21, 2024, Philip has reported 3 open-market purchases worth $506K and no sales on SEC Form 4. In the last 12 months: 1 buy ($205K).
Their filings also include grants and awards (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.